Table 2 Mean combination index values of NVP-AEW541 plus gemcitabine or afatinib in pancreatic cancer cell lines (three independent experiments)

BxPc-3

0.96 (0.92–1.08, Additive)

p=0.54

0.34 (0.29–0.44, Synergism)

p<0.05

AsPc-1

0.91 (0.86–0.95, Additive)

p<0.05

0.75 (0.68–0.84, Moderate Synergism)

p<0.05

FA-6

1.22 (1.07–1.33, Moderate antagonism)

p<0.05

0.8 (0.68–0.94, Moderate Synergism)

p=0.057

PANC-1

0.7 (0.56–0.84, Synergism)

p<0.05

0.73 (0.61–0.86, Moderate Synergism)

p<0.05

Capan-1

1.43 (1.31–1.52, Moderate antagonism)

p<0.05

0.9 (0.81–1.05, Slight Synergism/Additive)

p=0.34

MiaPaca-2

1.14 (1.02–1.27, Slight antagonism)

p=0.11

0.84 (0.78–0.91, Moderate Synergism)

p<0.05

PT45

1.09 (0.92–1.23, Additive)

p=0.36

1.44 (Moderate antagonism)

p<0.05